Utrecht, Netherlands

Maarten Van Der Kroef

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Maarten Van Der Kroef: Innovator in Antibody Technology

Introduction

Maarten Van Der Kroef is a notable inventor based in Utrecht, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. His innovative work has the potential to impact cancer therapy and diagnostic procedures.

Latest Patents

One of his key patents is titled "Antibodies capable of binding to OX40, variants thereof and uses thereof." This invention relates to antibodies that can bind to human OX40 and includes variants with a modified Fc region. These modifications enhance the Fc-Fc interaction while reducing the Fc effector functions of the antibody. The patent also covers pharmaceutical compositions that utilize these antibodies for therapeutic and diagnostic purposes, especially in cancer treatment. He holds 1 patent in this area.

Career Highlights

Throughout his career, Maarten has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Genmab A/S and BioNTech SE. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Maarten has worked alongside talented individuals such as Kristel Kemper and Dennis Verzijl. Their collaborative efforts have further advanced the research and development of innovative antibody therapies.

Conclusion

Maarten Van Der Kroef is a distinguished inventor whose work in antibody technology holds promise for improving cancer therapies. His contributions to the field exemplify the importance of innovation in biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…